VERIFIED MULTIOMYX MULTIPLEXING PANELS - IMMUNE PANEL (TIL PANEL) - 12 MARKERS - NEOGENOMICS ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Verified MultiOmyx™ Multiplexing Panels
Immune Panel (TIL panel) – 12 markers
Tested in multiple cancer indications (melanoma, lung, colorectal, prostate, breast)
TIL Panel Co-expression Phenotypes
CD3 CD3+CD4+ T helper
CD4 CD3+CD4+FoxP3+ T regulatory
CD8 CD3+CD4+CD45RO+ Memory T helper
CD45RO CD3+CD4+PD1+ Immune modulation
FoxP3 CD3+CD8+ T cytotoxic
CD20 CD3+CD8+CD45RO+ Memory T cytotoxic
CD68 CD3+CD8+PD1+ Immune modulation
CD56 CD68+ Macrophage PanCK+ CD8+ PD-L1+ CD68+ FoxP3+
Au Q. et al. (April, 2016). MultiOmyx™ multiplexed tumor infiltrating lymphocyte
CTLA-4 CD68+PDL1+ Macrophage PD-L1 panel provides comprehensive immunophenotyping from a single FFPE slide.
Poster presented at AACR Annual Meeting, New Orleans, LA.
PD-1 CD20+ B cell
PD-L1 CD20+PDL1+ B cell PD-L1
PanCK CD3-CD56+ Natural Killer cell
PanCK+PDL1+ Tumor cell PD-L1
Myeloid Panel – 10 markers
Tested in PDAC tissue
Myeloid Panel Co-expression Phenotypes
CD11b CD11b+CD33+ Myeloid cells
M1 TAM
CD14 CD11b+CD33+HLADR- MDSC
CD15 CD11b+CD33+HLADR-CD14+CD15- M-MDSC
CD16 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC
CD33 CD68+ TAM
CD68 CD68+HLADR+CD163- M1 TAM
CD163 CD68+HLADR-CD163+ M2 TAM
HLA-DR CD11b+HLADR-CD16+ Neutrophil/G-MDSC PanCK+ CD68+ CD11b+ HLA-DR+
Juncker-Jensen A. et al. (April, 2018). Tumor-Infiltrating Myeloid Cells – Using
Arginase1 MultiOmyx™ to Distinguish between MDSCs, TAMs and TANs in the Pancreatic
Tumor Microenvironment. Poster presented at AACR Annual Meeting, Chicago, IL.
PanCK
Verified MultiOmyx™ Multiplexing Panels
TIL & Myeloid Panel #1 – 16 markers
Tested in NSCLC tissue
TIL/TAM Panel #1 Co-expression Phenotypes
CD3 CD3+CD4+ T helper LAG3+/PD1+ CTL
CD4 CD3+CD4+FoxP3+ T regulatory
CD8 CD3+CD4+PD1+ Immune modulation
FoxP3 CD3+CD8+ T cytotoxic
CD20 CD8+PD1+ Immune modulation
CD68 CD3+TIM3+ Immune modulation
CD163 CD3+LAG3+ Immune modulation
CD3+ICOS+ Immune modulation PanCK+ LAG-3+ PD-1+ CD8+
CD11b
Juncker-Jensen A. et al. (2019, December). PD-1 and LAG-3 synergize to drive
CD15 CD3+OX40+ Immune modulation tumor-infiltration of T cytotoxic cells in NSCLC tumors. Poster presented at ESMO
I/O Annual Meeting, Geneva, Switzerland.
TIM-3 CD20+ B cell
LAG-3 CD11b+CD15+ Granulocyte
OX40 CD68+ TAM
ICOS CD68+CD163+ M2 TAM
PD-1 CD68+PDL1+ Macrophage PD-L1
PD-L1 CD68+TIM3+ Macrophage TIM-3
PanCK PanCK+PDL1+ Tumor cell PD-L1
TIL & Myeloid Panel #2 – 19 markers
Tested in PDAC tissue
TIL/Myeloid Panel Co-expression Phenotypes
#2
CD3+CD4+ T helper
CD3
CD3+CD4+FoxP3+ T regulatory
G-MDSC
CD4
CD3+CD4+PD1+ Immune modulation
CD8
CD3+CD8+ T cytotoxic
CD45RO
CD8+PD1+ Immune modulation
FoxP3
CD8+GranzymeB+ Effector T cytotoxic
CD11b
CD3+CD45RO Memory T cells
CD14 PanCK+ CD11b+ CD3+ CD15+ FoxP3+
CD68+ TAM
Juncker-Jensen A. et al. (October, 2018). Using MultiOmyx™ to Analyze
CD15
CD68+HLADR+CD163- M1 TAM Correlations between Immunosuppressive Cells and Tumor-Infiltrating
Lymphocytes in the Pancreatic Tumor Microenvironment. Poster presented at
CD16
CD68+HLADR-CD163+ M2 TAM ESMO Annual Meeting, Munich, Germany.
CD33
CD68+PDL1+ Macrophage PD-L1
CD68
CD11b+CD33+ Myeloid cells
CD163
CD11b+CD33+HLADR- MDSC
HLA-DR
CD11b+CD33+HLADR-CD14+CD15- M-MDSC
Arginase1
CD11b+CD33+HLADR-CD14-CD15+ G-MDSC
GranzymeB
PanCK+Ki67+ Proliferating tumor
Ki67
PanCK+PDL1+ Tumor cell PD-L1
PD-1
PD-L1
PanCK
2 | Verified MultiOmyx™ Multiplexing Panels
Dendritic Cell Panel – 15 markers
Tested in melanoma tissue
Dendritic Panel Co-expression Phenotypes
CD3 CD3+CD4+ T helper pDC
CD4 CD3+CD8+ T cytotoxic
CD8 CD68+ TAM
CD11c CD68+HLADR+CD163- M1 TAM
CD14 CD68+HLADR-CD163+ M2 TAM
CD40 CD123+HLADR+ pDC
CD68 CD123+HLADR+CD40+ CD40 positive pDC
CD123 CD123+HLADR+DCLAMP+ Activated pDC
CD141 CD11c+Clec9A+CD141+HLADR+ cDC
CD163 CD11c+Clec9A+CD141+CD40+ CD40 positive cDC SOX10+CD123+HLADR+CD11c+
Gozo M. et al. (2020, June). Distinguishing dendritic cell subtypes in the
HLA-DR CD11c+Clec9A+CD141+DCLAMP+ Activated cDC tumor microenvironment using MultiOmyxTM. Poster presented at AACR
Annual Meeting, Virtual.
Clec9A CD11c+CD14+DCSIGN+HLADR+ Monocyte derived DC
DC-SIGN
DC-LAMP
SOX10/PanCK
Tertiary Lymphoid Structure (TLS) Panel – 14 markers
Tested in bladder cancer tissue
TLS Panel Co-expression Phenotypes
CD3 CD3+CD4+ T helper
CD4 CD3+CD4+FoxP3+ T regulatory
CD8 CD3+CD8+ T cytotoxic
FoxP3 CD20+ B cell
CD11b CD11b+HLADR+ APC myeloid cell
CD14 CD11b+HLADR- MDSC
CD15 CD11b+HLADR-CXCR2+ MDSC positive for CXCR2
CD20 CD11b+HLADR-iNOS MDSC positive for iNOS
CD68 CD11b+HLADR-CD14+CD15- M-MDSC HEV
PNAd CD11b+HLADR-CD14+CD15- G-MDSC
CXCR2 CD68+ TAM
iNOS CD68+HLADR+ M1 TAM CD20+ PNAd+ CD3+
Image of TLS in a bladder cancer sample from an unpublished academic
HLA-DR CD68+iNOS+ M1 TAM collaboration study with University of Notre Dame.
PanCK PNAd+ High Endothelial Venule
PanCK+iNOS+ iNOS positive tumor cells
Verified MultiOmyx™ Multiplexing Panels | 3
TIL, TAM & Vessel Panel #1 – 10 markers
Tested in breast cancer tissue
TIL/TAM Panel #1 Co-expression Phenotypes
CD3 CD3+CD4+ T helper
CD4 CD3+CD4+FoxP3+ T regulatory
CD8 CD3+CD8+ T cytotoxic
FoxP3 CD68+ TAM
CD68 CD68+HLADR+CD163- M1 TAM
CD163 CD68+HLADR-CD163+ M2 TAM
PanCK+ CD3+ CD34+ Ki67+
HLA-DR CD34+ Vessels Juncker-Jensen A. et al. (April, 2019). Pro-Tumorigenic Mechanisms of M2 Tumor-
Associated Macrophages in Triple-Negative Breast Cancer. Poster presented at
Ki67 PanCK+Ki67+ Proliferating tumor AACR Annual Meeting, Chicago, IL.
CD34
PanCK
TIL, TAM & Vessel Panel #2 – 16 markers
Tested in ovarian tumor tissue
TIL/TAM Panel #2 Co-expression Phenotypes M1 TAM
CD3 CD3+CD4+ T helper
CD4 CD3+CD4+FoxP3+ T regulatory
M2 TAM
CD8 CD3+CD4+PD1+ Immune modulation
FoxP3 CD4+CTLA4+ Immune modulation
CD20 CD3+CD8+ T cytotoxic
CD68 CD8+PD1+ Immune modulation
CD163 CD8+CTLA4+ Immune modulation
HLA-DR CD20+ B cell
S100+ CD68+ HLA-DR+ CD163+
PD-1 CD68+ TAM Juncker-Jensen A. et al. (2019, October). An Integrated Multiplexing Approach for
the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell
PD-L1 CD68+HLADR+CD163- M1 TAM Tumors. Poster presented at AACR-NCI-EORTC Annual Meeting, Boston, MA.
CTLA-4 CD68+HLADR-CD163+ M2 TAM
CD34 CD68+PDL1+ Macrophage PD-L1
Vimentin CD34+ Vessels
S100 PanCK+Ki67+ Proliferating tumor
Ki67 PanCK+PDL1+ Tumor cell PD-L1
PanCK
4 | Verified MultiOmyx™ Multiplexing Panels
TIGIT Immune Cell Panel – 15 markers
Tested in NSCLC & melanoma tissue
TIGIT Immune Panel Co-expression Phenotypes
TIGIT CD3+CD4+ T helper
CD226 CD3+CD4+FoxP3+ T regulatory
CD155 CD3+CD4+PD1+ Immune modulation
CD3 CD3+CD8+ T cytotoxic
CD4 CD8+PD1+ Immune modulation
CD8 CD8+GranzymeB+ Effector T cytotoxic
SOX10 + TIGIT+ LAG3+ PD1+
FoxP3 CD68+ TAM
Au Q. et al. (April, 2019). Characterization of TIGIT Expression Using
MultiOmyx™ Hyperplexed Immunofluorescence Assay in NSCLC and melanoma.
CD56 CD68+HLADR+CD163- M1 TAM Poster presented at AACR Annual Meeting, Atlanta, GA.
CD45RO CD68+HLADR-CD163+ M2 TAM
CD11b CD68+PDL1+ Macrophage PD-L1
CD11c CD11b+CD33+ Myeloid cells
PD-1 CD11b+CD33+HLADR- MDSC
LAG-3 CD11b+CD33+HLADR-CD14+CD15- M-MDSC
TIM-3 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC
PanCK/SOX10 PanCK+Ki67+ Proliferating tumor
PanCK+PD1+ Tumor cell PD-L1
Myeloid Leukemia Immune Panel – 14 markers
Tested in AML/HL/DLBCL
Leukemia Panel Co-expression Phenotypes
CD3 CD3+CD4+ T helper G-MDSC
CD4 CD3+CD4+FoxP3+ T regulatory
CD8 CD3+CD8+ T cytotoxic
G-MDSC
FoxP3 CD68+ TAM
G-MDSC
CD68 CD68+HLADR+CD163- M1 TAM
CD163 CD68+HLADR-CD163+ M2 TAM
HLA-DR CD11b+CD33+ Myeloid cells
CD11b+CD33+CD15+CD34+
CD11b CD11b+CD33+HLADR- MDSC
Au Q. et al. (2019, December). Phenotypic Characterization of the Immune
CD33 CD11b+CD33+HLADR-CD14+CD15- M-MDSC Landscape in the Bone Marrow of Patients with Acute
Myeloid Leukemia (AML) Using MultiOmyx™ Hyperplexed Immunofluorescence
CD14 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC Assay. Poster presented at ASH Annual Meeting, Orlando, FL.
CD15 CD11b+CD33+HLADR-CD14-CD15+Arg1 Arg1+ G-MDSC
CD34
Arginase1
Tumor marker
Verified MultiOmyx™ Multiplexing Panels | 5
Hepatitis B (HBV) Panel – 19 markers
Tested in liver tissue
HBV Panel Co-expression Phenotypes
HBcAG CD3+CD4+ T helper
HBsAG CD3+CD4+FoxP3+ T regulatory
NaKATPase CD3+CD4+PD1+ Immune modulation
CD3 CD3+CD8+ T cytotoxic
CD4 CD3+CD8+PD1+ Immune modulation
CD8 CD68+ TAM
FoxP3 CD68+HLADR+ M1 macrophage
CD68+CD163+ M2 macrophage HBcAG+ HBsAG+ DAPI+
CD56
CD20 CD68+PDL1+ Macrophage PD-L1
CD11b CD68+DCSIGN+ Macrophage DC-SIGN
HLA-DR CD11b+HLADR- MDSC
CD11c CD11c+HLADR+ Dendritic cell (cDC)
DC-SIGN CD11c+HLADR+DCSIGN+ Dendritic cell
CD68 CD20+ B cell
Dendritic cell
CD163 CD20+HLADR+ B cell HLA-DR
PD-1 CD56+CD3- NK cell
PD-L1 CD56+CD3-HLADR+ NK cell HLA-DR CD11c+ HLADR+ CD68+ CD20+
IDO1
Ki67
NASH Liver Panel – 17 markers
Tested in liver tissue
NASH Panel Co-expression Phenotypes
CD11b CD11b+CD11c+CD14-HLADR+ cDC
HLA-DR CD11c+HLADR+CD14-IDO1+ cDC IDO1+
CD68 CD11b+CD11c+HLADR+CD14-Ki67+ cDC proliferating
CD163 CD68+CD163+CD16 Kupffer cell Kupffer cell
CD11c CD68+CD163+CD16+DCSIGN+ Kupffer cell DC-SIGN+
DC-SIGN CD68+CD163+CD16+PDL1+ Kupffer cell PD-L1+
CD66b Kupffer cell prolifer-
CD68+CD163+CD16+Ki67+ ating CD68+ CD16+ CD163+
CD9
CD68+CD163+CD16+CD33+ Kupffer cell CD33+
CD14
CD11b+CD14+HLADR+ Tmo
CD16
CD11b+CD14+HLADR+CD16+ TMo CD16+
CD33
HLADR+CD9+CD14+ SAM
SMA
HLADR+CD9+CD14+TREM2+ SAM TREM2+
TREM2
HLADR+CD9+CD14+PDL1+ SAM PD-L1+
MNDA
HLADR+CD9+CD14+DCSIGN+ SAM DC-SIGN+
IDO1
HLADR+CD9+CD14+CD33+ SAM CD33+
PD-L1
HLADR+CD9+CD14+MNDA+ SAM MNDA+
Ki67 HLADR+ CD16+ CD14+ CD9+
HLADR+CD9+CD14+Ki67+ SAM proliferating
PD-L1
PanCK
6 | Verified MultiOmyx™ Multiplexing Panels
Verified MultiOmyx™ Multiplexing Panels | 7
About NeoGenomics
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced
oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus,
sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and
research clients to meet program objectives and delivery from biomarker discovery through companion CDx
validation and commercialization.
About Neogenomics Pharma Services
NeoGenomics’ Pharma Services unifies several innovative companies’ scientific and medical leadership under
one leading brand, offering one of the most comprehensive laboratory services menu available for biomarker
testing supporting oncology clinical trials globally.
We provide our clients with an unparalleled level of expertise, service, flexibility, and scalability. Additionally,
we offer alternative business models and solutions across the continuum of development from pre-clinical
research and development through commercialization.
To learn more about NeoGenomics Pharma Services, visit us online at https://neogenomics.com/pharma-
services. NeoGenomics Pharma Services can be your research partner with NGS or other innovative
services.
Please contact NeoGenomics Pharma Services at 800.720.4363 or email at
pharmaservices@neogenomics.com.
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing, partnership
opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic
services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-
accredited, CLIA-certified laboratories.
Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro
diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics
welcomes your inquiries for collaborations. Please contact us for more information.
12701 Commonwealth Dr., Suite 9 NeoGenomics Europe, S.A.
Fort Myers, FL 33913 United States A-One Business Center
Phone: 866.776.5907 Bâtiment A5, 2nd Floor
Fax: 239.690.4237 Z.A. La Pièce / Route de l’Etraz 1
1180 Rolle, Switzerland
31 Columbia
Phone: +41.21.721.06.00
Aliso Viejo, CA 92656 United States
Fax: +41.(0)21.826.00.73
Phone: 800.720.4363
Fax: 949.425.5865 NeoGenomics Singapore Pte. Ltd.
7256 S. Sam Houston Pkwy W., Suite 300 61 Science Park Road, #02-11
Houston, TX 77085 United States Singapore 117525
Phone: 800.720.4363 / 713.528.4363 Phone: +65.69115202
Fax: 713.668.3565
Suzhou NeoGenomics Pharmaceutical
NeoGenomics Laboratories, Inc. Research Co., Ltd
4570 Executive Drive., Suite 250 Building 6, Block 19, Yong’An Road
San Diego, CA 92121 Huguan Industrial Park,
Phone: 949.445.7300 x5056 Suzhou New District, China
© 2021 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners. Rev.012621
You can also read
